Molecular Templates
Market Cap
US$726.3m
Last Updated
2020/05/28 03:51 UTC
Data Sources
Company Financials +
Executive Summary
Molecular Templates, Inc., a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Excellent balance sheet with limited growth.
Share Price & News
How has Molecular Templates's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MTEM's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-0.06%
MTEM
-0.7%
US Biotechs
2.0%
US Market
1 Year Return
88.7%
MTEM
23.4%
US Biotechs
7.1%
US Market
Return vs Industry: MTEM exceeded the US Biotechs industry which returned 23.4% over the past year.
Return vs Market: MTEM exceeded the US Market which returned 7.1% over the past year.
Shareholder returns
| MTEM | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.06% | -0.7% | 2.0% |
| 30 Day | -3.0% | 3.3% | 6.0% |
| 90 Day | -1.2% | 14.4% | -0.05% |
| 1 Year | 88.7%88.7% | 24.6%23.4% | 9.5%7.1% |
| 3 Year | n/a | 34.6%30.1% | 30.7%22.1% |
| 5 Year | n/a | -3.1%-8.9% | 55.6%38.0% |
Price Volatility Vs. Market
How volatile is Molecular Templates's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Does The Molecular Templates, Inc. (NASDAQ:MTEM) Share Price Tend To Follow The Market?2 months ago | Simply Wall St
Is Molecular Templates (NASDAQ:MTEM) Using Too Much Debt?3 months ago | Simply Wall St
What Kind Of Shareholder Owns Most Molecular Templates, Inc. (NASDAQ:MTEM) Stock?Valuation
Is Molecular Templates undervalued compared to its fair value and its price relative to the market?
8.67x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MTEM's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MTEM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MTEM is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: MTEM is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MTEM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MTEM is overvalued based on its PB Ratio (8.7x) compared to the US Biotechs industry average (3.7x).
Next Steps
Future Growth
How is Molecular Templates forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
13.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MTEM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MTEM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MTEM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MTEM's revenue (35.1% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: MTEM's revenue (35.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MTEM's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Molecular Templates performed over the past 5 years?
-48.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MTEM is currently unprofitable.
Growing Profit Margin: MTEM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MTEM is unprofitable, and losses have increased over the past 5 years at a rate of -48.6% per year.
Accelerating Growth: Unable to compare MTEM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MTEM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: MTEM has a negative Return on Equity (-101.8%), as it is currently unprofitable.
Next Steps
Financial Health
How is Molecular Templates's financial position?
Financial Position Analysis
Short Term Liabilities: MTEM's short term assets ($124.2M) exceed its short term liabilities ($43.8M).
Long Term Liabilities: MTEM's short term assets ($124.2M) exceed its long term liabilities ($33.1M).
Debt to Equity History and Analysis
Debt Level: MTEM's debt to equity ratio (3.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if MTEM's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MTEM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MTEM has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 37.1% each year.
Next Steps
Dividend
What is Molecular Templates's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MTEM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MTEM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MTEM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MTEM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MTEM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.5yrs
Average management tenure
CEO
Eric Poma (47yo)
11.33yrs
Tenure
US$1,733,738
Compensation
Dr. Eric E. Poma, Ph.D., is the Chief Executive Officer and Chief Scientific Officer of Molecular Templates, Inc. since 2009 and served as it's President. Dr. Poma served as Vice President of Business Deve ...
CEO Compensation Analysis
Compensation vs Market: Eric's total compensation ($USD1.73M) is below average for companies of similar size in the US market ($USD3.13M).
Compensation vs Earnings: Eric's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Chief Scientific Officer & Director | 11.33yrs | US$1.73m | 0.52% $3.8m | |
| President & COO | 10.33yrs | US$1.08m | 0.12% $860.2k | |
| Chief Medical Officer | 1.25yrs | US$1.32m | no data | |
| Chief Financial Officer | 2.5yrs | US$1.07m | no data | |
| Executive Vice President of Corporate Development | no data | no data | no data | |
| Executive VP of Operations & Head of Manufacturing | no data | no data | no data | |
| Executive Vice President of R&D | no data | no data | no data | |
| Executive Vice President of Manufacturing | no data | no data | no data | |
| Senior Vice President of Clinical Development | 2.5yrs | no data | no data | |
| Senior Vice President of Finance & Corporate Controller | 2.5yrs | no data | no data |
2.5yrs
Average Tenure
46yo
Average Age
Experienced Management: MTEM's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Chief Scientific Officer & Director | 11.33yrs | US$1.73m | 0.52% $3.8m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.75yrs | US$157.55k | no data | |
| Chairman | no data | US$172.55k | 0.089% $648.4k | |
| Independent Director | no data | US$160.55k | no data | |
| Independent Director | 2.75yrs | US$159.05k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2yrs | no data | no data | |
| Independent Director | 2.75yrs | US$150.05k | no data |
2.8yrs
Average Tenure
50yo
Average Age
Experienced Board: MTEM's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.3%.
Top Shareholders
Company Information
Molecular Templates, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Molecular Templates, Inc.
- Ticker: MTEM
- Exchange: NasdaqCM
- Founded:
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$726.297m
- Shares outstanding: 45.71m
- Website: https://www.mtem.com
Number of Employees
Location
- Molecular Templates, Inc.
- 9301 Amberglen Boulevard
- Suite 100
- Austin
- Texas
- 78729
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MTEM | NasdaqCM (Nasdaq Capital Market) | Yes | New Common Shares | US | USD | Aug 2017 |
| NZW2 | DB (Deutsche Boerse AG) | Yes | New Common Shares | DE | EUR | Aug 2017 |
Biography
Molecular Templates, Inc., a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin’s lymphoma. The company also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 targeting CD38. It has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted conditioning regimens to enhance the hematopoietic stem cell transplant process. Molecular Templates, Inc. is headquartered in Austin, Texas.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/05/28 03:51 |
| End of Day Share Price | 2020/05/27 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.